NCT06567925

Brief Summary

Nearly one-third of US adults have poor sleep quality. Sleep quality refers to sleep efficiency, sleep latency, sleep duration, wake after sleep onset, and movement during the night. Specifically, sleep efficiency (SE) measures how well an individual utilizes their time in bed for restorative sleep and it highly depends on actual sleep duration. Reduced SE is associated with a greater risk for heart failure (HF), which affects \~6.7 million adults in the US alone. HF with preserved ejection fraction (HFpEF) accounts for about half of all HF diagnoses and is associated with poor prognosis (30-50% 5-year mortality from diagnosis) and severely reduced quality of life (QoL). Long-term goal for the investigators is to identify sleep modulation as a potential therapeutic target to improve QoL in HFpEF, with poor SE being present in \~60% of patients with HFpEF. The study is aimed to see if the sleep modulation is feasible and modulating sleep can improve the QoL and functional capacity along with the reduction of inflammation among subjects with HFpEF.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 1, 2024

Completed
22 days until next milestone

First Posted

Study publicly available on registry

August 23, 2024

Completed
5 months until next milestone

Study Start

First participant enrolled

January 21, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 4, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 4, 2025

Completed
Last Updated

September 4, 2025

Status Verified

August 1, 2025

Enrollment Period

3 months

First QC Date

August 1, 2024

Last Update Submit

August 27, 2025

Conditions

Keywords

Sleep EfficiencySleep ExtensionHeart Failure with Preserved Ejection FractionQuality of Life

Outcome Measures

Primary Outcomes (4)

  • Demonstrate the feasibility of a gradual sleep extension strategy combined with sleep hygiene training using a wearable device

    To assess the sleep modulation, We will assess sleep quality using the two wearable devices. A research-based accelerometer (GT9X Link, ActiGraph, FL) will be used on the wrist using a 24-hour per day for 7 days wear protocol except shower and swimming for the 1-week run-in phase. The same wear protocol will be implemented for the 2 weeks of intervention. Sleep duration and rest in bed will be automatically detected by the Actigraph and translated by Actilife software with an epoch of 30 seconds.

    Between baseline and 2 weeks of the intervention

  • Demonstrate the feasibility of a gradual sleep extension strategy combined with sleep hygiene training using a sleep journal

    A sleep diary will be used to reinforce the assessment conducted by accelerometer. A sleep diary is a record of your sleep behaviors, quality and schedule. It can help you to gauge your total sleep time, mark your breaks in sleep and when they occur and track changes in your quality of sleep.

    Between baseline and 2 weeks of the intervention

  • Demonstrate the feasibility of a gradual sleep extension strategy combined with sleep hygiene training using the Pittsburgh Sleep Quality questionnaire.

    Pittsburgh Sleep Quality questionnaire: Pittsburgh Sleep Symptom Questionnaire - Insomnia (PSSQ\_I) has 13 self-rated questions. Only questions 1,2 or 5 are used to determine the presence, frequency AND duration of sleep symptom criteria. Questions 6-13 are used to identify significant daytime consequences of the sleep complaint. Adding up the average scores of the seven factors gives a global PSQI score from 0 to 21, with 0-4 indicating "good" sleep and 5-21 indicating "poor" sleep

    Baseline (week 1) and at the end of the follow-up period (week 3)

  • Demonstrate the feasibility of a gradual sleep extension strategy combined with sleep hygiene training using the Epworth Sleepiness Scale at baseline and at the end of the follow-up for subjectively assess sleep quality.

    Epworth Sleepiness Scale: The Epworth sleepiness scale results range from 0 to 24. Results from 0 to 10 show average (normal) daytime sleepiness. A result under 10 may not be cause for concern or it could identify you have trouble sleeping (insomnia). A result from 11 to 24 indicates excessive (abnormal) daytime sleepiness.

    Baseline (week 1) and at the end of the follow-up period (week 3)

Study Arms (1)

Gradual sleep extension strategy

EXPERIMENTAL

Demonstrate the feasibility of a gradual sleep extension strategy combined with sleep hygiene training aimed at increasing sleep efficiency in patients with heart failure with preserved ejection fraction on guideline-directed medical therapy

Behavioral: Customized Sleep CoachingBehavioral: Sleep Hygiene Training

Interventions

Demonstrate the feasibility of a gradual sleep extension strategy using customized sleep coaching.

Gradual sleep extension strategy

Sleep hygiene training aimed at increasing sleep efficiency in patients with heart failure with preserved ejection fraction on guideline-directed medical therapy

Gradual sleep extension strategy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • confirmed clinical diagnosis of stable HF (NYHA class II-III)
  • left ventricular ejection fraction\>50% documented in the prior 12 months
  • aged ≥18 years
  • habitual reported sleep duration ≤7 hours
  • sleep efficiency \<85% measured during the 1-week run-in phase

You may not qualify if:

  • concomitant conditions that can limit physical activity
  • severe debilitating diseases (ischemic heart disease. angina, arterial fibrillation, moderate to severe valvular disease)
  • taking sleep medicine or melatonin irregularly
  • pregnancy
  • stage V kidney disease (with dialysis)
  • shift worker
  • insomnia
  • hospitalization within the last 2 months
  • patients with sleep and circadian disorders
  • fluid overload
  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Virginia Commonwealth University

Richmond, Virginia, 23298, United States

Location

Study Officials

  • Salvatore Carbone

    Virginia Commonwealth University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Single-arm open-label feasibility study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 1, 2024

First Posted

August 23, 2024

Study Start

January 21, 2025

Primary Completion

May 4, 2025

Study Completion

May 4, 2025

Last Updated

September 4, 2025

Record last verified: 2025-08

Locations